Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
The Standard-Times on MSN4d
New Bedford man stole over $450K from disabled veteran. Here's what we know.Hundreds of thousands in monthly veteran benefits were stolen by New Bedford man. Here's what he was sentenced: ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
Joseph Smith, 71, was sentenced to 23 months in prison to be followed by two years of supervised release. He was charged with ...
A New Bedford man was sentenced to prison for conspiring to steal and then depositing over $450,000 from a U.S. Marine ...
Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback